Sangamo Therapeutics, Inc. (SGMOQ)
OTCMKTS · Delayed Price · Currency is USD
0.0675
-0.0025 (-3.57%)
Jul 21, 2026, 3:50 PM EST
Sangamo Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 27.59 | 20.95 | 41.92 | 45.2 | 100.44 | 178.87 |
Short-Term Investments | - | - | - | 35.8 | 177.19 | 197.68 |
Cash & Short-Term Investments | 27.59 | 20.95 | 41.92 | 81 | 277.63 | 376.55 |
Cash Growth | 9.55% | -50.03% | -48.25% | -70.82% | -26.27% | -41.30% |
Total Trade Receivables | 6.36 | 10.51 | 4.6 | 4.07 | 4.47 | 6.36 |
Other Current Assets | 3.16 | 4.37 | 5.18 | 9.26 | 18.22 | 15.86 |
Total Current Assets | 37.11 | 35.83 | 51.69 | 94.33 | 300.33 | 398.77 |
Net Property, Plant & Equipment | 13.22 | 14.11 | 34.76 | 52.87 | 125.53 | 124.7 |
Other Intangible Assets | - | - | - | - | 50.73 | 53.76 |
Goodwill | - | - | - | - | 37.55 | 39.7 |
Long-Term Investments | - | - | - | - | 29.85 | 88.17 |
Other Long-Term Assets | 9.63 | 9.81 | 15.19 | 18.13 | 18.52 | 16.82 |
Total Assets | 59.97 | 59.75 | 101.64 | 165.32 | 562.51 | 721.92 |
Accounts Payable | 19.31 | 14.44 | 15.49 | 15.26 | 22.42 | 9.76 |
Accrued Expenses | 33.43 | 27.13 | 22.76 | 32.47 | 37.51 | 32.42 |
Unearned Revenue | 0.4 | 0.9 | 7.56 | - | 51.78 | 85.71 |
Total Current Liabilities | 53.13 | 42.47 | 45.81 | 47.73 | 111.71 | 127.89 |
Long-Term Leases | 19.33 | 25.09 | 26.25 | 33.52 | 38.99 | 44.06 |
Other Long-Term Liabilities | 6.45 | 6.45 | 6.81 | 1.19 | 116.85 | 174.64 |
Total Long-Term Liabilities | 25.79 | 31.55 | 33.06 | 34.7 | 155.84 | 218.69 |
Total Liabilities | 78.92 | 74.01 | 78.87 | 82.43 | 267.55 | 346.58 |
Common Stock | 4.14 | 3.51 | 2.13 | 1.78 | 1.67 | 1.46 |
Additional Paid-in Capital | 1,638 | 1,611 | 1,532 | 1,492 | 1,450 | 1,334 |
Accumulated Other Comprehensive Income | -2.51 | -1.46 | -7.53 | -4.6 | -8.4 | -3.99 |
Retained Earnings | -1,658 | -1,627 | -1,504 | -1,406 | -1,149 | -956.27 |
Total Common Shareholders' Equity | -18.96 | -14.27 | 22.77 | 82.89 | 294.96 | 375.34 |
Shareholders' Equity | -18.96 | -14.27 | 22.77 | 82.89 | 294.96 | 375.34 |
Total Liabilities & Equity | 59.97 | 59.75 | 101.64 | 165.32 | 562.51 | 721.92 |
Total Debt | 19.33 | 25.09 | 26.25 | 33.52 | 38.99 | 44.06 |
Net Cash (Debt) | 8.25 | -4.15 | 15.67 | 47.49 | 238.65 | 332.49 |
Net Cash Growth | - | - | -67.01% | -80.10% | -28.23% | -44.86% |
Net Cash Per Share | 0.03 | -0.01 | 0.08 | 0.27 | 1.55 | 2.30 |
Book Value | -18.96 | -14.27 | 22.77 | 82.89 | 294.96 | 375.34 |
Book Value Per Share | -0.06 | -0.05 | 0.11 | 0.48 | 1.91 | 2.60 |
Tangible Book Value | -18.96 | -14.27 | 22.77 | 82.89 | 206.68 | 281.88 |
Tangible Book Value Per Share | -0.06 | -0.05 | 0.11 | 0.48 | 1.34 | 1.95 |